| 232.03 7.34 (3.27%) | 02-27 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 274.77 | 1-year : | 320.93 |
| Resists | First : | 235.25 | Second : | 274.77 |
| Pivot price | 226.66 |
|||
| Supports | First : | 216.1 | Second : | 204.27 |
| MAs | MA(5) : | 228.05 |
MA(20) : | 225.52 |
| MA(100) : | 224.31 |
MA(250) : | 205.84 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 65.7  |
D(3) : | 70.1 |
| RSI | RSI(14): 57.3 |
|||
| 52-week | High : | 241.11 | Low : | 159.05 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ABBV ] has closed below upper band by 20.6%. Bollinger Bands are 18.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 228.27 - 229.64 | 229.64 - 230.66 |
| Low: | 217.87 - 219.68 | 219.68 - 221.02 |
| Close: | 222.3 - 224.99 | 224.99 - 226.98 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Sat, 28 Feb 2026
Westfield Capital Management Co. LP Takes $1.84 Million Position in AbbVie Inc. $ABBV - MarketBeat
Sat, 28 Feb 2026
Harvest Portfolios Group Inc. Has $66.12 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Sat, 28 Feb 2026
Huntington National Bank Purchases 24,310 Shares of AbbVie Inc. $ABBV - MarketBeat
Sat, 28 Feb 2026
American Century Companies Inc. Cuts Stake in AbbVie Inc. $ABBV - MarketBeat
Fri, 27 Feb 2026
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term - Nasdaq
Wed, 25 Feb 2026
RBC Capital Initiates Coverage of AbbVie (ABBV) with Outperform Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 1,770 (M) |
| Held by Insiders | 1.76e+009 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 19,710 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.942e+010 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 6.9 % |
| Operating Margin | 34.9 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 1 % |
| Qtrly Rev. Growth | 6.116e+010 % |
| Gross Profit (p.s.) | 30.3 |
| Sales Per Share | 323.24 |
| EBITDA (p.s.) | 1.32788e+011 |
| Qtrly Earnings Growth | 2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.71 |
| Price to Cash Flow | -50.77 |
| Dividend | 0 |
| Forward Dividend | 1.968e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|